Depression trials in Hungary

In Hungary 8 Also abroad 666

8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Where
Budapest, Budapest III
Age
18 years to 65 years
People
360 worldwide
Run by
Seaport Therapeutics
See details and how to joinNCT07065240 · EU 2025-521240-37-00
Phase 2Enrolling by invitation
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
Where
Budapest, Budapest III, Pécs
Age
18 years to 66 years
People
360 worldwide
Run by
Seaport Therapeutics
See details and how to joinNCT07161700 · EU 2025-522347-18-00
Phase 2Not yet taking people in Hungary
A Study of Brenipatide in Participants With Major Depressive Disorder
Where
Budapest, Gyöngyös
Age
18 years to 75 years
People
330 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07928245 · EU 2026-527689-65-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Where
Budapest, Debrecen, Győr, Szeged
Age
12 years to 17 years
People
258 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07227454 · EU 2024-518615-19-00
Phase 3Taking people
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Where
Budapest, Budapest III, Gyongyos, Kalocsa
Age
18 years and over
People
850 worldwide
Run by
Neurocrine Biosciences
See details and how to joinNCT06966401 · EU 2024-519423-24-00
Phase 3Taking people
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Where
Budapest, Budapest III, Gyongyos, Kalocsa
Age
18 years and over
People
200 worldwide
Run by
Neurocrine Biosciences
See details and how to joinNCT06963021 · EU 2024-519421-37-00
Phase 4Not yet taking people in Hungary
Evaluation of the efficacy of Trazodone in improving emotional blunting symptoms in Patients with Major Depressive Disorder
Where
Gyongyos, Pécs
Age
18 years to 64 years
People
120 worldwide
Run by
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
See details and how to join2025-523267-38-00 · EU 2025-523267-38-00
No phaseEnrolling by invitation
Effect of Theta-burst rTMS Therapy on the Clinical and Cognitive Symptoms of Patients With Therapy Resistant Depression and Response Prediction With Neuroimaging Methods.
Where
Budapest
Age
18 years and over
People
54
Run by
Semmelweis University
See details and how to joinNCT07207239